Theranostic systems by integrating the tumor imaging and tumor therapeutic capabilities into one platform have attracted numerous attentions from worldwide researchers. Despite the great developments, their clinical application is still in the nascent stage, owing to the unsatisfied imaging quality and limited therapeutic efficacy. Fortunately, the emerging of aggregation‐induced emission (AIE) molecules with unique fluorescence property offers an opportunity to solve the imaging problem. Besides, further utilizing the tumor microenvironments and external triggers to design the stimuli‐responsive imaging‐guided therapy could enhance the therapeutic efficacy and reduce the side effects. In this review, the advancements in stimuli‐responsive theranostic systems with AIE characteristics are summarized. Theranostic systems are first classified according to their treatment modes, and then subdivided based on various stimuli, including pH, redox, enzyme, and light. In each section, the design strategies and application examples are introduced. At last, the current state of the art, limitations, as well as prospects are also discussed.

No abstract

Purpose To study prognostic values of the clinicopathological characteristics and survival outcomes in micropapillary urothelial carcinoma (MPUC) of the urinary bladder. Method We used the national Surveillance, Epidemiology, and End Results database (2004‐2016) to compare MPUC with transitional cell carcinoma (TCC) and to investigate prognostic values of clinicopathological characteristics, as well as survival outcomes, in MPUC of the urinary bladder. A multivariable Cox proportional hazard model, subgroup analyses, and propensity score matching were used. Results In all, 519 patients with MPUC and 154 453 patients with TCC were enrolled. Compared with TCC, patients with MPUC had a higher rate of muscle invasive disease ( P < .001), lymph node metastasis ( P < .001), and distal metastasis ( P < .001), as well as higher tumor grade ( P < .001). According to the survival analyses, the MPUC group also had lower survival probability in both cancer‐specific mortality (CSM) ( P < .0001) and overall mortality (OM) analyses ( P < .0001). Cox proportional hazard regression showed that the MPUC group had a higher risk of OM (hazard ratios [HR] = 1.39, 95% confidence intervals [CI] = 1.22‐1.57, P < .0001), although the CSM (HR = 1.18, 95% CI = 1.00‐1.40, P = .0505) in that group was fair. In the subgroup analysis, only MPUC patients without distal metastasis faced a higher risk of CSM (HR = 1.33, 95% CI = 1.101.61, P < .0001). Conclusions Micropapillary urothelial carcinoma prognosis is poorer than that of TCC. Micropapillary urothelial carcinoma is an independent prognostic factor for OM in patients with urinary bladder cancer.

Recently, the issue of cancer has attracted extensive attention. Early diagnosis and timely therapy are important for cancer treatment. And lots of advanced fluorescent probes have been applied to cancer theranostics. However, the further development of these probes is limited by the disadvantages of poor targeting, weak sensitivity and photobleaching. Fortunately, the emergence of biomolecule-conjugated fluorescent probes with aggregationinduced emission properties has taken innovative impetus to the cancer theranostics. This review summarizes the rational fabrication and biomedical applications of biomolecule-conjugated AIE luminogens (AIEgens) based on "click reaction" over the past decade. In the meantime, the challenges of biomolecule-conjugated AIEgens in the field of biomedicine are also discussed.

Objective: To investigate the diagnostic role of magnetic resonance imaging (MRI)-targeted biopsy (TB) for prostate cancer (PCa) in biopsy-naïve men. Materials and Methods: Own control studies and randomized controlled trials (RCTs) up to December 2018 were identified via a systematic search of PubMed, Embase, Ovid, and the Cochrane Library. We pooled relative sensitivity (or risk ratio [RR]) to compare diagnostic efficiency for PCa and clinically significant PCa (csPCa) between TB and systematic biopsy (SB). The independent role of either biopsy pathway was evaluated for participants with positive/negative MRI. Results: Thirty-one studies consisting of 25 own control studies and 6 RCTs were included. We identified 4,020 biopsy-naïve men with positive MRI who underwent two biopsies concurrently, with PCa/csPCa detection rates of 65.90 and 45.13%, respectively. TB and SB did not differ in the detection of any PCa (RR 0.98, 95% confidence interval [CI] 0.92-1.05). However, TB detected more csPCa (RR 1.19, 95% CI 1.10-1.30) and more PCa with a Gleason score ≥3+4 (RR 1.20, 95% CI 1.07-1.34). Using a combined test as a reference, omitting SB resulted in detecting 12.81% less csPCa and 20.76% less clinically insignificant PCa (cinsPCa), and omitting TB resulted in detecting 25.69% less csPCa and 10.8% more cinsPCa. For patients with negative MRI, omitting SB led to underdetection of 30.29% of any PCa (10.9% of csPCa). Conclusions: Combining TB and SB increased the diagnostic accuracy of csPCa for biopsy-naïve men with positive MRI, and omitting SB for patients with a negative MRI would lead to the underdetection of nearly 10% of csPCa.

Introduction: We aimed to develop an easy-to-use individual survival prognostication tool based on competing risk analyses to predict the risk of 5-year cancer-specific death after radical prostatectomy for patients with prostate cancer (PCa).Methods: We obtained the data from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2016). The main variables obtained included age at diagnosis, marital status, race, pathological extension, regional lymphonode status, prostate specific antigen level, pathological Gleason Score. In order to reveal the independent prognostic factors. The cumulative incidence function was used as the univariable competing risk analyses and The Fine and Gray's proportional subdistribution hazard approach was used as the multivariable competing risk analyses. With these factors, a nomogram and risk stratification based on the nomogram was established. Concordance index (C-index) and calibration curves were used for validation.Results: A total of 95,812 patients were included and divided into training cohort (n = 67,072) and validation cohort (n = 28,740). Seven independent prognostic factors including age, race, marital status, pathological extension, regional lymphonode status, PSA level, and pathological GS were used to construct the nomogram. In the training cohort, the C-index was 0.828 (%95CI, 0.812–0.844), and the C-index was 0.838 (%95CI, 0.813–0.863) in the validation cohort. The results of the cumulative incidence function showed that the discrimination of risk stratification based on nomogram is better than that of the risk stratification system based on D'Amico risk stratification.Conclusions: We successfully developed the first competing risk nomogram to predict the risk of cancer-specific death after surgery for patients with PCa. It has the potential to help clinicians improve post-operative management of patients.

Highly effective transporting and real‐time monitoring of the drug delivery system (DDS) has attracted much attention from researchers. However, separately tracking the multiple components in a complex DDS as well as its delivery process is challengeable. Here, a multi‐fluorescence‐labeled ternary complex is designed for delivering the therapeutic agents and monitoring the multiple components. Ternary complex (A@TR) is formed by three parts, including a) the carrier module TFD, which is a cell‐penetrating peptide (TAT) conjugated with anti‐cancer drug doxorubicin (DOX) and fluorescent molecule fluorescein isothiocyanate (FITC); b) therapeutic genes (ASO); c) the targeting module RDP based on a cyclic RGDFK peptide and aggregation‐induced‐emission luminogen PyTPE. The labeling of FITC through the covalent bond can stably track the location of anticancer drugs and genes in the long term. Meanwhile, the mark of PyTPE can monitor the process of targeting‐mediated endocytosis over time. After being internalized by tumor cells selectively, chemodrug and therapeutic genes can achieve a superior tumor inhibited effect. By utilizing the multi‐channel fluorescence, this ternary complex could achieve precisely monitoring the targeted binding process of DDS and delivery processes of therapeutic agents.

Prostate cancer (PCa) is the second-most common cancer among men. Both active surveillance or watchful waiting (AS/WW) and focal laser ablation (FLA) can avoid the complications caused by radical treatment. How to make the choice between these options in clinical practice needs further study. Therefore, this study aims to compare and analyze their effects based on overall survival (OS) and cancer-specific survival (CSS) to obtain better long-term benefits. We included patients with low-risk PCa from the Surveillance Epidemiology and End Results database of 2010–2016. Multivariate Cox proportional hazard analyses were conducted for OS and CSS in the two groups. To eliminate bias, this study applied a series of sensitivity analyses. Moreover, Kaplan–Meier curves were plotted to obtain survival status. A total of 18 841 patients with low-risk PCa were included, with a median of 36-month follow-up. According to the multivariate Cox proportional hazard regression, the FLA group presented inferior survival benefits in OS than the AS/WW group (hazard ratio [HR]: 2.13, 95% confidence interval [CI]: 1.37–3.33, P < 0.05). After adjusting for confounders, the result persisted (HR: 1.69, 95% CI: 1.02–2.81, P < 0.05). According to the results of the sensitivity analysis, the inverse probability of the treatment weighing model indicated the same result in OS. In conclusion, AS/WW and FLA have the advantage of fewer side effects and the benefit of avoiding overtreatment compared with standard treatment. Our study suggested that AS/WW provides more survival benefits for patients with low-risk PCa. More relevant researches and data will be needed for further clarity.